Late Phase Market Outlook: 2018-2022
$4,460.00 – $8,920.00
Related products
-
Improving Patient Recruitment in Biosimilar Trials
$3,260.00 – $6,520.00 -
CRO Quality Benchmarking – Phase II/III Service Providers (4th edition)
$6,800.00 – $13,600.00 -
The Phase I Market Overview and Outlook
$4,900.00 – $7,350.00 -
CRO Quality Benchmarking – Phase IV Service Providers (4th edition)
$4,900.00 – $9,800.00